Cellbox's $5.4M Raise Signals a New Era for Shipping Living Cells

Jan de Vries · 2026-10-20

Cellbox Solutions, a German logistics tech company, just closed its Series A at €5 million (about $5.4 million). That's a big deal for a niche that most people never think about: moving living cells and tissues without freezing them. ### From €3.5M to €5M: The Final Close The company first announced a €3.5 million ($3.8 million) close in March 2026. Now, additional investors have come on board, including members of Baltic Business Angels Invest GmbH. Existing backers NRW.BANK and Fraunhofer Venture also participated again. So what's the plan for the fresh cash? Cellbox wants to expand beyond just hardware. It's building out integrated logistics services for sensitive biological materials—think rental programs, recurring services, and end-to-end monitoring. "With the successful completion of our Series A round, we are now expanding our established warm-chain technology platform into a broader offering for physiological logistics," says Prof. Dr. Kathrin Adlkofer, founder and CEO. "This will allow us to support customers more comprehensively across their logistics workflows and expand our presence in key international markets." ### Why Warm-Chain Logistics Matters Most people have heard of cold chain—the refrigerated trucks and freezers that keep vaccines and food fresh. But some biological materials can't be frozen. Living cells, organoids, and tissues need a controlled environment that mimics the human body: around 98.6°F (37°C) and specific CO₂ levels. That's where Cellbox comes in. Its portable CO₂ incubators, the Cellbox Go and Cellbox Shipper, create a regulated environment during ground and air transport. Temperature and CO₂ are individually adjustable, so researchers and clinicians can maintain reproducible conditions from lab to bedside. "Over the past years, we have built a strong foundation for the controlled transport of living biological materials," Adlkofer adds. ### A Growing Sector Cellbox's raise is part of a broader wave of European life sciences funding in 2026. Here's a quick snapshot of other recent deals: - **Scinus Group** (Netherlands) – €3 million ($3.2 million) for cell expansion - **Cellply** (Italy) – €7.15 million ($7.7 million) for cell therapy quality control - **Tozaro** (UK) – €6.9 million ($7.4 million) for cell and gene therapy manufacturing - **Primogene** (Germany) – €4.1 million ($4.4 million) for enzymatic biomanufacturing - **QT Sense** (Netherlands) – €4 million ($4.3 million) - **ALP Bio** (Switzerland) – €1.9 million ($2 million) Together with Cellbox, these deals add up to roughly €32 million ($34.5 million) across related but distinct technologies. ### The Commercial Push The company, founded in 2017 and based in Cologne, already has over 400 Cellbox systems in use worldwide. Now it's focusing on turning that technological edge into sustainable commercial growth. "Completion of the Series A gives us additional resources to scale the commercial model behind our technology," says Dr. Bernd Muehlenweg, CBO and CFO. "By expanding rental and recurring service offerings and combining them with transportation, monitoring, and complementary logistics services, we can build longer-term customer relationships and a more scalable service model across markets." In short, Cellbox is moving from selling boxes to offering a full service—one that could become essential as cell therapies and advanced biologics become more common. > "Our focus is now on translating the strength of the Cellbox platform into sustainable commercial growth." — Dr. Bernd Muehlenweg For those in biotech and pharma logistics, that's a development worth watching.